COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS

Elahe Mohammadi Jorjafki; Zahra Karimizadeh; Ali Shahi; Hanye Sohrabi

doi:10.18502/igj.v5i3.16036

Elahe Mohammadi Jorjafki Students’ International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Zahra Karimizadeh Students’ International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Ali Shahi Students’ International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hanye Sohrabi Students’ International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

DOI: https://doi.org/10.18502/igj.v5i3.16036

Keywords: severe acute respiratory syndrome coronavirus 2; Disseminated intravascular Coagulation; Pulmonary embolism; COVID-19

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a various clinical and laboratory finding in affected patients. Similar to the previous outbreak, patients with SARS-CoV-2 showed elevated levels of D-dimer, thrombocytopenia, prolonged prothrombin time, and the activated partial thromboplastin time. Meanwhile, two lethal coagulation disorders of disseminated intravascular coagulation and pulmonary embolism have already been reported in patients with SARS-CoV-2. Although further cohort studies are needed to document long-term complications, considering the similar pathogenicity of SARS-CoV and SARS-CoV-2, the same chronic cardiovascular impairments could be expected.